Research & Regulatory News

A Trial That Had to Move Two Things at Once

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Bliddal and colleagues published once-weekly semaglutide in persons with obesity and knee osteoarthritis in the New England Journal of Medicine in October 2024. The trial, NCT05064735, enrolled 407 participants with co-primary endpoints of percentage change in body weight and change in WOMAC pain score.

Key facts

Registration
NCT05064735
Registered acronym
None
Phase
3
Enrolment
407
Status
Completed
Primary completion
24 July 2023
Co-primary 1
Percentage change in body weight
Co-primary 2
Change in WOMAC pain score
Published
NEJM, 31 October 2024 (PMID 39476339)

Why two co-primary endpoints is the notable design choice

The registry lists both percentage change in body weight and change in WOMAC pain score as primary outcomes. Requiring a trial to move two endpoints is a harder test than either alone, and it reflects the specific claim being made. The claim is not that the drug reduces weight, which was established, but that doing so changes what the joint disease does to people.

What WOMAC measures

The Western Ontario and McMaster Universities Osteoarthritis Index is a patient-reported instrument covering pain, stiffness and physical function. It asks people what they experience rather than measuring cartilage on a scan, which makes it a symptomatic endpoint. Symptoms are what bring people with osteoarthritis to clinicians.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why the mechanical argument is strong here

The knee bears load, and the force it experiences during walking is several times body weight because muscle contraction across the joint adds to gravitational load. Reducing body mass therefore reduces joint force by a multiple of the mass lost. Unlike most indications for this class, the primary mechanism requires nothing beyond the weight change itself.

What it does not establish

Structural change. A symptomatic improvement is not evidence that cartilage was preserved or that disease progression slowed. Those are separate endpoints requiring imaging and much longer follow-up, and osteoarthritis has a long history of symptomatic effects that did not translate into structural ones.

The naming point, for the third time

NCT05064735 carries no registered acronym. This site has now found three widely discussed trials in the same position, the CagriSema head-to-head and the tirzepatide adolescent Phase 3 being the others. Searching a programme name on ClinicalTrials.gov can return nothing while the trial exists under its number.

How this fits the indication pattern

Cardiovascular events, kidney events, liver histology, heart failure, walking capacity in peripheral artery disease and now joint symptoms. The pattern is a metabolic agent being assessed organ system by organ system, with osteoarthritis unusual in that the proposed mechanism is mechanical rather than metabolic.

The boundary

Semaglutide is a licensed medicine and this was a registered trial conducted under clinical supervision. Nothing supplied on this site is semaglutide, is related to it, or is an alternative to any treatment for osteoarthritis.

Frequently asked questions

What were the trial's primary endpoints?

Two: percentage change in body weight and change in WOMAC pain score. Moving both is a harder test than either alone.

What is WOMAC?

A patient-reported instrument covering pain, stiffness and physical function in osteoarthritis. It measures symptoms rather than joint structure.

Does it show the joint disease was slowed?

No. Symptomatic improvement is not structural evidence, which would require imaging endpoints and much longer follow-up.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.